Source: Yahoo! Finance – February 8, 2018
Q BioMed Inc. (QBIO), is pleased to announce an exclusive option agreement with Washington University in St. Louis. Under the agreement granting the exclusive right to license the technology, Q BioMed will evaluate the feasibility and usability of GDF-15, a novel biomarker for monitoring glaucoma, as a companion diagnostic to the MAN-01 small molecule currently being optimized for the topical treatment of glaucoma.
“The ophthalmology in general and glaucoma sector specifically are currently in an active consolidation and business development cycle. Having access to a truly innovative technology that compliments ours as a companion diagnostic could greatly enhance the value of the Mannin Research MAN-01 technology. We are excited to evaluate this technology and look forward to a new collaborative partnership with a leading institution like Washington University School of Medicine,” said Denis Corin, CEO of Q BioMed, Inc.Read Full Article